Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald V Swanson

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Journal of Molecular Recognition : JMR|March 13, 2012
Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chainJuan Carlos Almagro, Gopalan Raghunathan, Eric Beil, et al.
Structure (London, England : 1993)|December 7, 2002
Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallographyJacek Nowakowski, Ciarán N Cronin, Duncan E McRee, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Journal of Molecular Biology|March 16, 2010
Human framework adaptation of a mouse anti-human IL-13 antibodyJohan Fransson, Alexey Teplyakov, Gopalan Raghunathan, et al.
JCI Insight|April 3, 2025
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasiaJacqueline H Starrett, Clara Lemoine, Matthias Guillo, et al.
The Journal of Biological Chemistry|June 19, 2014
Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-lifeWilson Edwards, Wai-Ping Fung-Leung, Chichi Huang, et al.
Cell Metabolism|February 19, 2019
A Long-Acting PYY<sub>3-36</sub> Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman PrimatesShamina M Rangwala, Katharine D'Aquino, Yue-Mei Zhang, et al.
Structure (London, England : 1993)|July 10, 2004
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylasesJohn R Somoza, Robert J Skene, Bradley A Katz, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Journal of Molecular Recognition : JMR|March 13, 2012
Characterization of a high-affinity human antibody with a disulfide bridge in the third complementarity-determining region of the heavy chainJuan Carlos Almagro, Gopalan Raghunathan, Eric Beil, et al.
Structure (London, England : 1993)|December 7, 2002
Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallographyJacek Nowakowski, Ciarán N Cronin, Duncan E McRee, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Journal of Molecular Biology|March 16, 2010
Human framework adaptation of a mouse anti-human IL-13 antibodyJohan Fransson, Alexey Teplyakov, Gopalan Raghunathan, et al.
JCI Insight|April 3, 2025
TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasiaJacqueline H Starrett, Clara Lemoine, Matthias Guillo, et al.
The Journal of Biological Chemistry|June 19, 2014
Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-lifeWilson Edwards, Wai-Ping Fung-Leung, Chichi Huang, et al.
Cell Metabolism|February 19, 2019
A Long-Acting PYY<sub>3-36</sub> Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman PrimatesShamina M Rangwala, Katharine D'Aquino, Yue-Mei Zhang, et al.
Structure (London, England : 1993)|July 10, 2004
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylasesJohn R Somoza, Robert J Skene, Bradley A Katz, et al.
Pageof 3